7.24
News
Price History
Option Chain
Financials
Insider Trading
Why NVAX Down?
Discussions
Forecast
Stock Split
Dividend History
Novavax, Inc. Stock (NVAX) Latest News

Seeking Alpha
Stocks To Watch: Eyes On Government Shutdown Drama, New Spinoffs And Auto Sector Updates

The Motley Fool
Why Pfizer and BioNTech Stocks Zoomed Higher Today

The Motley Fool
Does This Message From Moderna Mean Bad News for Novavax?

The Motley Fool
You Can Pick Up These High-Risk, High-Reward Stocks for Less Than $10

Zacks Investment Research
Moderna (MRNA) Receives CHMP Nod for Updated COVID Vaccine

The Motley Fool
Why COVID Vaccine Demand Might Not Be That Strong

The Motley Fool
Novavax Is a Step Behind, Again. Should You Be Worried?

The Motley Fool
Up 20% in 1 Month, Is This Stock a Buy?

Zacks Investment Research
The Zacks Analyst Blog Highlights Pfizer, BioNTech, Moderna and Novavax

Zacks Investment Research
FDA Approves Pfizer & Moderna's New COVID Booster Vaccines

Benzinga
Moderna, Pfizer Get FDA Nod For Omicron COVID Boosters While Novavax Waits
MarketWatch
New Pfizer and Moderna COVID shots approved by FDA

Zacks Investment Research
Novavax (NVAX) Up 36.8% Since Last Earnings Report: Can It Continue?

Zacks Investment Research
Moderna (MRNA) Updated COVID Jab Effective Against Pirola Variant

Zacks Investment Research
Stocks on the Mend: A Mean Reversion Duo

The Motley Fool
This Down-on-Its-Luck Biotech Could Surge 150%, Wall Street Says. Should You Buy the Stock?

The Motley Fool
Why Novavax Stock Rocketed 10% Higher Today

Zacks Investment Research
Novavax (NVAX) Stock Increases 9% in a Month: Here's Why

The Motley Fool
Coronavirus Cases Are on the Rise -- Should You Buy Vaccine Stocks?

The Motley Fool
Should You Buy Novavax's Stock Before the FDA Approves Its New COVID Shot?

Zacks Investment Research
Pfizer (PFE) & BioNTech Get CHMP Nod for Updated Covid-19 Jab

The Motley Fool
Why Novavax Stock Was So Healthy on Monday

Benzinga
Why NovoCure Are Trading Lower By Around 31%? Here Are Other Stocks Moving In Monday's Mid-Day Session
MarketWatch
COVID is evolving quickly in white-tailed deer, study finds

Benzinga
Jabil, Boston Scientific, Hersha Hospitality Trust And Other Big Stocks Moving Higher On Monday

The Motley Fool
COVID Is Making a Comeback: Should You Buy These 2 Stocks?

Zacks Investment Research
The Zacks Analyst Blog Highlights Regeneron Pharmaceuticals, Gilead Sciences, Novavax, Apellis Pharmaceuticals and Fulcrum Therapeutics

The Motley Fool
Are These 2 Companies Next for Short Squeezes?

Zacks Investment Research
Biotech Stock Roundup: REGN Up on Approval, APLS, NVAX Gain on Updates & More
MarketWatch
Nvidia stock rises ahead of results, Foot Locker and Peloton tank, and other stocks on the move

Zacks Investment Research
Novavax (NVAX) Updated COVID Jab Effective Against Eris Variant
MarketWatch
Nvidia stock rises ahead of results, AMC shares slump and other stocks on the move.

Zacks Investment Research
The Zacks Analyst Blog Highlights Moderna, BioNTech, Novavax and Pfizer

The Motley Fool
Why Are Shares of Novavax Soaring Today?

Zacks Investment Research
U.S. Govt to Urge Citizens to Get New COVID-19 Shots

The Motley Fool
Why Moderna, BioNTech SE, and Novavax Surged Today
MarketWatch
As COVID hospitalizations rise, Pfizer and Moderna say updated shots show promise against Eris variant
MarketWatch
As COVID hospitalizations rise, Pfizer and Moderna say updated shots show promise against Eris variant

Zacks Investment Research
Moderna (MRNA) Updated COVID Jab Effective Against Eris Variant

The Motley Fool
Novavax Posted a Profit in Q2. Here's Why It Doesn't Matter
MarketWatch
WHO names Eris a coronavirus variant of interest. Here’s what you need to know.
MarketWatch
WHO names Eris a coronavirus variant of interest. Here’s what you need to know.

The Motley Fool
2 Beaten-Down Stocks That Still Aren't Worth Buying

The Motley Fool
Why Novavax Stock Blasted 8% Higher Today

Benzinga
Why Krispy Kreme Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
MarketWatch
WHO names Eris a COVID variant of interest. Here’s what you need to know.

Benzinga
Alibaba, Illumina, CyberArk Software And Other Big Stocks Moving Higher On Thursday

Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For August 9, 2023

Zacks Investment Research
Novavax (NVAX) Q2 Earnings Beat, Stock Down 4% on '23 Sales Cut

Benzinga
Bank Downgrades Trigger Stock Sell-Off; Treasuries, Dollar Rally Amid Safe-Haven Demand: What's Driving Markets Tuesday?
About Novavax, Inc.
Novavax, Inc., together with its subsidiary, Novavax AB, a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of recombinant nanoparticle vaccines and adjuvants. Its lead adjuvant is Matrix-M that is used to enable a vaccine to enhance the amplitude of the immune response and qualitatively change it, enhance its specificity to provide protection against related microorganisms, as well as allows immunization with much lower doses of antigen. The company develops respiratory syncytial (RSV) virus fusion protein nanoparticle vaccine candidate for infants via maternal immunization in Phase III clinical trial; older adults in Phase II clinical trial; and children six months to five years of age in Phase I clinical trial. Novavax, Inc. also develops NanoFlu vaccine, which is in Phase I/II clinical trial for treating seasonal influenza in older adults; and Ebola virus glycoprotein vaccine that is in Phase I clinical trial. Its preclinical programs include Zika virus; combination respiratory vaccine candidate to protect against RSV and seasonal influenza, as well as other infectious disease vaccine candidates. Novavax, Inc. was founded in 1987 and is headquartered in Gaithersburg, Maryland.
Cap:
|
Volume (24h):